# Data Sheet (Cat.No.T2347)



#### BLU9931

### **Chemical Properties**

CAS No.: 1538604-68-0

Formula: C26H22Cl2N4O3

Molecular Weight: 509.38

Appearance: no data available

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

## **Biological Description**

| Description   | BLU9931 is the first selective small molecule inhibitor of FGFR4.   |
|---------------|---|
| Targets(IC50) | FGFR  |
| In vitro      | In MDA-MB-453 cells, BLU9931 potently inhibits phosphorylation of FGFR4 signaling pathway. BLU9931 inhibits proliferation of HCC cell lines that express an intact FGFR4 signaling complex, such as Hep 3B, HUH-7, and JHH-7 cell lines, with EC50 of <1 $\mu$ M. BLU9931 also inhibits proliferation in PDX-derived cell lines with an intact FGFR4 signaling pathway. [1]   |
| In vivo       | In mice bearing the FGF19-amplified Hep 3B liver tumors, BLU9931 (300 mg/kg, p.o.) leads to tumor regression and prevents this weight loss induced by tumors. In mice bearing the FGF19-overexpressing PDX-derived LIXC012 xenografts, treatment with BLU9931 (300 mg/kg, p.o.) also leads to tumor regression. [1]   |
| Kinase Assay  | FGFR1-4 Biochemical Assays: FGFR kinase inhibition assays are performed at KM for ATP. Picomolar to low nanomolar concentrations of FGFR proteins are incubated in 1× Kinase Reaction Buffer (KRB) with 1 $\mu$ M of CSKtide and 50 to 250 of $\mu$ M ATP at 25°C for 90 minutes in the presence or absence of a dosed concentration series of inhibitor. All reactions are terminated by the addition of Stop buffer, and plates are read on a Caliper EZReader2. IC50 values are fit with a four-parameter log[Inhibitor] versus response model with floating Hill Slope. |
| Cell Research | Established and PDX-derived HCC cell lines are seeded in 96-well plates in respective growth media, allowed to attach overnight, and treated with a dilution series of test compounds for two cell-doubling times. Cell viability is determined by CellTiter-Glo, and results represented as background-subtracted relative light units normalized to a DMSO-treated control. Relative EC50 values are determined at 50% inhibition between the top and bottom plateau of the dose-response curve.(Only for Reference)  |

## **Solubility Information**

| Solubility | DMSO: 5.09 mg/mL (9.99 mM), Sonication is recommended.          |  |
|------------|---|--|
|            | (< 1 mg/ml refers to the product slightly soluble or insoluble) |  |
|            | l   |  |

Page 1 of 2 www.targetmol.com

#### **Preparing Stock Solutions**

|       | 1mg       | 5mg       | 10mg       |
|-------|-----------|-----------|------------|
| 1 mM  | 1.9632 mL | 9.8159 mL | 19.6317 mL |
| 5 mM  | 0.3926 mL | 1.9632 mL | 3.9263 mL  |
| 10 mM | 0.1963 mL | 0.9816 mL | 1.9632 mL  |
| 50 mM | 0.0393 mL | 0.1963 mL | 0.3926 mL  |

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

#### Reference

Hagel M, et al. Cancer Discov. 2015, 5(4), 424-437.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:36 Washington Street,Wellesley Hills,MA 02481

Page 2 of 2 www.targetmol.com